Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer.

ABSTRACT:

Background

SCALOP, a randomised, phase II trial, tested the activity and safety of gemcitabine (GEM)-based and capecitabine (CAP)-based chemoradiation (CRT) for locally advanced pancreatic cancer (LAPC). Here we present the long-term outcomes.

Methods

Eligibility: histologically proven LAPC ⩽7 cm. Following 12 weeks of induction GEMCAP chemotherapy (three cycles: GEM 1000 mg m^-2 days 1, 8, 15; CAP 830 mg m^-2 days 1-21 q28 days) patients with stable/responding disease, tumour ⩽6 cm, and WHO Performance Status 0-1 were randomised to receive one cycle GEMCAP followed by CAP (830 mg m^-2 b.d. on weekdays only) or GEM (300 mg m^-2 weekly) with radiation (50.4 Gy per 28 fractions).

Results

One-hundred fourteen patients (28 UK centre

SUBMITTER: Hurt CN 

PROVIDER: S-EPMC5482737 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature